COL1A2 and systemic sclerosis: Treatment of SSc fibroblasts (n = 6) with roscovitine resulted in 20–30% reduction (p < 0.05) in cellular Type I collagen and αSMA levels (Figure 6A), and >40% reduction in COL1A2 mRNA (Figure 6B).